An innovative approach to capacity management.
Is the contract-only CMO an endangered species?
Measuring the size of the market for contract manufacturing services requires a careful hand.
The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Service providers must focus on delivering a superior customer experience.
The evolving bio/pharmaceutical business model poses risk for CMOs.
Some recent private-equity buyouts of CROs show both the upside and downside for investors.
A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.
CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.